ArticlePloS one2009
Effective treatment of respiratory alphaherpesvirus infection using RNA interference.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Where should siRNAs go: applicable organs for siRNA drugs.Experimental & molecular medicine · 2023Review
- Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.Kona : powder science and technology in Japan · 2016Article
- Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics.Molecular therapy. Nucleic acids · 2013Article
- RNAi Therapeutic Platforms for Lung Diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Clinical translation of RNAi-based treatments for respiratory diseases.Drug delivery and translational research · 2013Article
- Progress toward in vivo use of siRNAs-II.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Review
- Pulmonary delivery of therapeutic siRNA.Advanced drug delivery reviews · 2012Review
- Modeling RNA interference in mammalian cells.BMC systems biology · 2011Article
- The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses.Virus research · 2010Article
- Intracranial administration of P gene siRNA protects mice from lethal Chandipura virus encephalitis.PloS one · 2010Article
- Lipidic systems for in vivo siRNA delivery.The AAPS journal · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEquine herpesvirus type 1 (EHV-1), a member of the Alphaherpesvirinae, is spread via nasal secretions and causes respiratory disease, neurological disorders and abortions. The virus is a significant equine pathogen, but current EHV-1 vaccines are only partially protective and effective metaphylactic and therapeutic agents are not available. Small interfering RNAs (siRNA's), delivered intranasally, could prove a valuable alternative for infection control. siRNA's against two essential EHV-1 genes, encoding the viral helicase (Ori) and glycoprotein B, were evaluated for their potential to decrease EHV-1 infection in a mouse model. METHODOLOGY/PRINCIPAL FNDINGS: siRNA therapy in vitro significantly reduced virus production and plaque size. Viral titers were reduced 80-fold with 37.5 pmol of a single siRNA or with as little as 6.25 pmol of each siRNA when used in combination. siRNA therapy in vivo significantly reduced viral replication and clinical signs. Intranasal treatment did not require a transport vehicle and proved effective when given up to 12 h before or after infection. CONCLUSIONS/SIGNIFICANCE: siRNA treatment has potential for both prevention and early treatment of EHV-1 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.